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doi:10.1016/j.jtcvs.2006.12.064bjectives: Endothelial dysfunction and C-reactive protein play a pivotal role in
evelopment of atherosclerosis and act as markers for future adverse cardiac events.
tatins reduce C-reactive protein levels and improve endothelial function. However,
ittle information is available on endothelial function and its determinants in veins. We
nvestigated the association between saphenous vein endothelial function and C-reactive
rotein levels in patients treated with statins undergoing coronary artery bypass surgery.
ethods: Seventy-six patients with optimal low-density lipoprotein cholesterol
evels (1.6 mmol/L) secondary to regular treatment with a minimum of simva-
tatin 40 mg were recruited. Each subject underwent detailed characterization
ccording to anthropomorphic data, saphenous vein endothelial function (assessed
x vivo by measuring acetylcholine-induced relaxation of venous rings), and mark-
rs of systemic inflammation (C-reactive protein and tumor necrosis factor-).
esults: Despite regular treatment with statins, 26% of patients had C-reactive
rotein levels in the “high-risk” range (3.0 mg/L). There was a negative linear
orrelation between acetylcholine-induced venous relaxation and C-reactive protein
r  .30, P  .02) and waist circumference (r  0.21, P  .03). In a
ultivariate regression model, C-reactive protein (P  .02) was the only indepen-
ent predictor of acetylcholine-induced venous relaxation. In turn, correlates of
-reactive protein were assessed. There was a correlation between C-reactive
rotein and coronary atherosclerotic burden (r  .46, P  .0001), body mass index
r  .26, P  .03), fasting glucose levels (r  .31, P  .01), and waist circum-
erence (r  .29, P  .01). Using multivariate analysis, coronary atherosclerotic
urden (P  .0001) was the only independent predictor of C-reactive protein.
onclusions: In our cohort of patients with coronary artery disease, C-reactive
rotein level was the only independent predictor of saphenous vein endothelial
unction. In turn, its levels were independently influenced by the extent of coronary
therosclerotic burden.
ndothelial dysfunction and systemic inflammation play a pivotal role in the
pathophysiology of coronary artery atherosclerosis and acute coronary
events.1,2 Both have also been shown to be accurate predictors of futureardiovascular risk.1,2 Endothelial dysfunction is thought to be the earliest detect-
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CSPble composite manifestation of a number of vascular
athophysiologic changes leading to the development of
therosclerosis and is often present prior to the development
f morphologic/clinical manifestations of atherosclerosis.1,2
arkers of systemic inflammation such as C-reactive pro-
ein (CRP) have also emerged as potential participants in the
evelopment of atherosclerosis.2-4 CRP exerts a direct
roinflammatory effect on endothelial cells3 and may pro-
ote the development of clinical complications of athero-
clerosis such as arterial thrombosis.4 Of particular rele-
ance to the present report, in vitro studies have shown that
RP can reduce the production and bioactivity of the potent
ntiatherosclerotic signaling molecule nitric oxide (NO),5,6
hich is a key step in endothelial dysfunction.
Statins, which lower cholesterol by inhibiting the en-
yme 3-hydroxy-3-methylglutaryl-coenzyme A reductase,
re established as standard therapy for patients with coro-
ary artery disease (CAD). Independent of their lipid-low-
ring effect, statins have also been shown to improve en-
othelial function in arterial conduits and reduce CRP levels
n patients with CAD.7,8
Studies investigating the role of endothelial dysfunction
n development and clinical manifestations of atherosclero-
is and its association with inflammatory markers such as
RP are primarily derived from work on peripheral and
oronary arterial conduits. In contrast, there is limited in-
ormation on the function of the venous endothelium and its
eterminants. Considering that venous conduits remain an
mportant tool in surgical revascularization of patients with
AD, we examined factors influencing endothelial function
n saphenous vein samples of patients undergoing coronary
rtery bypass graft (CABG) surgery who were treated with
tatins.
aterials and Methods
atients
eventy-six unselected patients referred for elective first-time
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ACh  acetylcholine
BMI  body mass index
CABG  coronary artery bypass graft
CAD  coronary artery disease
CRP  C-reactive protein
HDL  high-density lipoprotein
LDL  low-density lipoprotein
L-NMMA  NG monomethyl-L-arginine
NO  nitric oxide
QCA  quantitative coronary angiography
SNP  sodium nitroprusside
TNF  tumor necrosis factor-ABG surgery between January 2003 and June 2004 were re- e
36 The Journal of Thoracic and Cardiovascular Surgery ● Auguruited to the study. Patients with symptomatic heart failure (New
ork Heart Association class II–IV), an acute coronary syndrome
ithin the previous 6 months, concurrent infection, or an inflam-
atory disorder (such as rheumatoid arthritis, which may have led
o an elevation in CRP levels) were excluded. One month prior to
dmission for surgery, each patient was reviewed to establish
moking status (nonsmoker, previous smoker, or current smoker),
o undergo detailed anthropomorphic measurements according to
ublished guidelines9 (weight [kg], height [m], waist and hip
ircumference [cm], body mass index [BMI, kg/m2] and waist–
o–hip ratio), and to ensure daily medication with a minimum of
imvastatin 40 mg.10 On the morning of surgery, blood was taken
or full lipid profile (total cholesterol, triglycerides, low-density
ipoprotein [LDL] cholesterol, and high-density lipoprotein [HDL]
holesterol), markers of systemic inflammation (high-sensitivity
RP, tumor necrosis factor- [TNF]), and serum blood glucose
fter an overnight fast. During surgery, a sample of saphenous vein
as obtained from each patient to assess vasomotor responses as
reviously reported11 and outlined below. Vasoactive medication
as omitted 24 hours prior to blood sampling and saphenous vein
arvest. The extent of coronary atherosclerotic burden was esti-
ated retrospectively from preoperative coronary angiograms.12
he study protocol and collection of tissue specimens had local
esearch ethics committee approval, and all subjects provided
ritten informed consent prior to recruitment to the study.
ssessment of Saphenous Vein Vasomotor Response
asomotor responses to phenylephrine, acetylcholine (ACh), and
odium nitroprusside (SNP) were assessed ex vivo in saphenous
ein rings as previously described.11 A 3-cm length of saphenous
ein was harvested at the start of the surgical procedure in each
atient. To ensure minimal interference with vascular function,
eins were harvested at the start of the surgical procedure using an
pen technique without distension and with minimal tissue han-
ling prior to administration of heparin and/or antifibrinolytic
rugs (for example, aprotonin). The venous rings were transferred
mmediately to the physiology laboratory in chilled, preoxygen-
ted Kreb’s Henseleit buffer without exposure to any medication.
one of the venous rings had been exposed to cardiopulmonary
ypass prior to and/or during harvesting. All venous rings under-
ent physiologic examination within hours of harvesting on the
ame day. Veins were carefully cleared of adherent tissue and
ectioned into 6 to 8, 4-mm rings. Rings were suspended between
fixed support and a force transducer in an organ bath containing
0 mL Krebs Henseleit solution at 37°C and bubbled with a
ixture of 95% O2/5% CO2. All experiments were performed in
he presence of indomethacin (10 mol/L) to inhibit
yclooxygenase.
Forty-five minutes were allowed for equilibration at a resting
ension of 3 g (determined from previous work in our laboratory).
o check the integrity of the smooth muscle cells in the saphenous
ein samples, the maximal contractile response of the vein to KCL
80 mmol/L) was assessed. Venous rings that contracted to 1 g
ere discarded. The samples were then washed and reequilibrated.
cumulative dose–response curve to phenylephrine (109103
ol/L) was performed. Samples underwent a second washout.
enous rings were preconstricted to 70% of the maximal phenyl-phrine-induced tension and relaxation responses to cumulative
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Poses of ACh (109104 mol/L) and SNP (1010104 mol/L)
easured in separate venous rings. To assess basal NO production,
henylephrine dose response studies (109103 mol/L) were
erformed before and after exposure to the nonselective NO syn-
hase inhibitor NG monomethyl-L-arginine (L-NMMA [104 mol/
]) in a third venous ring. Vasodilator responses were expressed as
percentage of the preconstricted tension.
easurement of Atherosclerotic Plaque Burden
oronary atherosclerotic burden was derived by calculating the
oronary atheroma extent score from preoperative angiograms in
ach patient as described by Sullivan and colleagues.12 A single
xperienced angiographer (N.M.), blinded to the patient’s vascular
unction and inflammatory status, reviewed all angiograms. Cor-
nary segments were analyzed in 1 angiographic view. Where
ossible, angiographic frames were analyzed in end diastole or
iastasis and selected to achieve minimal foreshortening and over-
ap, good visualization of stenoses within the segment, and optimal
ontrast and image quality. Coronary segments with a diameter of
1.5 mm were excluded from analysis. Philips (Eindhoven, The
etherlands) quantitative coronary angiography (QCA) software
ackage was used for analysis. Coronary catheters were used for
alibration, assuming the following diameters: 6F  1.95 mm, 5F
1.65 mm. Coronary extent score was derived by calculating the
roportion of each coronary artery and major side branch involved
n angiographically detectable atheroma (identified as any abnor-
al luminal narrowing or irregularity) and multiplied by a specific
actor reflecting the general surface area of that vessel. The overall
xtent score was derived from the sum of the scores obtained for
ach vessel to give a maximum total score out of 100. The factors
or each coronary artery and its branch were as follows: left main
rtery, 5; left anterior descending artery, 20; major diagonal
ranch or branches, 10; first septal perforator, 5; left circum-
ex artery, 20; obtuse marginal artery and its posterolateral
ranch together, 10; right coronary artery, 10; posterior de-
cending artery, 10. In patients where the major lateral wall
ranch was an obtuse marginal or intermediate artery, this vessel
as given a factor of 20, and the left circumflex artery, a factor
f 10. Occluded arteries were given the highest extent score
alculated in a corresponding artery in the entire study group.
oronary extent scores were calculated for 56 of the 76 patients
ecruited to the study. Fourteen angiograms were not available for
nalysis, and 6 angiograms were excluded as QCA was not pos-
ible in all coronary territories. To assess reproducibility, extent
cores were calculated on 2 different occasions separated by at
east 4 weeks in a random group of 15 patients. The reader
emained blinded to previous atheroma score obtained, as well as
atients’ vascular function and inflammatory status. Intraobserver
eproducibility was high, with a Pearson correlation coefficient of
.89 between 2 readings (P  .01).
aboratory Assays
ssays for full lipid profile and glucose were performed in the
ospital biochemistry department. Serum samples for CRP and
NF were stored at 80°C and analyzed at the end of the
ecruitment period. CRP was measured using a high-sensitivity
urbidimetric immunoassay (WAKO Chemicals, Neuss, Germany)
n the Cobas Mira Analyser (Roche Diagnostics, Lewes, UK). The i
The Journal of Thoracicowest detectable CRP concentration was 0.2 mg/L. Within-batch
ariability was assessed, and a coefficient of variation of 5% at 5.0
g/L was achieved. TNF was measured using a commercially
vailable enzyme-linked immunosorbent assay (R&D systems,
bingdon, UK). Between-batch variability was 10% at 13.5 g/L.
tatistical Analysis
ata analysis was performed with SPSS 12.0 for Windows statis-
ics software. Continuous variables were presented as mean 
EM. Non-normally distributed data (HDL cholesterol, triglycer-
des, glucose, TNF, and CRP) were log transformed for subse-
uent analysis. Pearson’s correlation coefficients were derived to
ssess the relationship between baseline variables and the vasodi-
ator response to ACh/ACh EC50 (concentration of ACh required
o produce 50% of the maximum possible response) and circulat-
ng CRP levels. A stepwise multiple regression model was pro-
uced to identify independent determinants of the vasodilator
esponse to ACh (model 1) and circulating CRP levels (model 2).
n Model 1, maximal vasodilator response to ACh was the depen-
ent variable and age, BMI, waist circumference, HDL choles-
erol, LDL cholesterol, plasma triglycerides, serum glucose, sys-
olic blood pressure, diastolic blood pressure, TNF, CRP, and
moking status as covariates. In model 2, circulating CRP level
as the dependent variable and age, BMI, waist circumference,
DL cholesterol, LDL cholesterol, plasma triglycerides, serum
lucose, systolic blood pressure, diastolic blood pressure, smoking
tatus, and coronary atherosclerotic burden as covariates. Statisti-
al significance was accepted at P  .05.
esults
 total of 76 patients were recruited to the study. Table 1
ummarizes the baseline clinical characteristics. Seven pa-
ients had 2-vessel coronary artery disease and the remain-
er, 3-vessel disease. All patients had been established on a
inimum of simvastatin 40 mg 1 month prior to surgery. In
ll patients, total cholesterol was 3.1 mmol/L (120.8
g/dL), and LDL cholesterol was 1.6 mmol/L (61.7
g/dL). Although lipid profile was adequately controlled in
ll patients, CRP levels remained over 3.0 mg/L in 26% of
atients. ACh-induced saphenous vein relaxation varied be-
ween 6.5% and 97%, indicating a wide range of venous
ndothelial function between patients. Venous relaxation to
NP was 80% in all rings, suggesting normal responsive-
ess of the vascular smooth muscle to exogenous NO.
actors Influencing Vascular Function in Human
aphenous Vein
he association between baseline characteristics of the 76
atients as outlined above and endothelium-dependent and
independent vasodilatation in saphenous vein samples was
nvestigated. Using univariate analysis, there was a signif-
cant negative correlation between ACh-induced venous
elaxation and logCRP (r  .30, P  .02) and waist
ircumference (r  0.21, P  .03). In a stepwise multi-
ariate regression model, logCRP (P  .02) was the only
ndependent predictor of ACh-induced venous relaxation
and Cardiovascular Surgery ● Volume 134, Number 2 337
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CSPigure 1. A, Negative correlation between maximal acetylcholine
ACh)-induced saphenous vein relaxation and C-reactive protein
CRP) levels. B, Positive correlation between coronary athero-
clerotic burden (as expressed by the coronary extent score) and
RP levels.ABLE 1. Baseline characteristics of patients
ge (y) 66.6 0.9
ale 92%
nthropomorphic measurements
Weight (kg) 79.9 1.4
BMI (kg/m2) 27.1 0.8
Waist (cm) 99.8 1.1
Hip (cm) 98.9 0.7
Waist:hip ratio 1.0 0.01
ull lipid profile
Total cholesterol (mmol/L) 3.1 0.1
LDL cholesterol (mmol/L) 1.6 0.1
HDL cholesterol (mmol/L) 0.9 0.03
Triglycerides (mmol/L) 1.3 0.1
asting glucose (mmol/L) 6.1 0.2
ystolic BP (mm Hg) 138.1 2.5
iastolic BP (mm Hg) 74.9 1.3
iabetes 20%
moking status
Current smoker 14%
Previous smoker 51%
Nonsmoker 35%
umber of native coronary arteries with 50%
stenosis
Single vessel 0%
Two vessels 9%
Three vessels 91%
eft ventricular function
Poor (EF  30%) 1%
Moderate (EF 30–50%) 19%
Good (EF  50%) 80%
arkers of systemic inflammation
CRP (mg/L) 2.4 0.2
1 30%
1–3 44%
3 26%
NF (g/L) 3.2 0.32
CE inhibitors 43%
ntiplatelet agent 100%
tatins 100%
alues presented as mean  standard error of mean (SEM) or % of total
atient population. ACE, Angiotensin-converting enzyme; BMI, body mass
ndex; BP, blood pressure; CRP, C-reactive protein; EF, ejection fraction;
DL, high-density lipoprotein; LDL, low-density lipoprotein; TNF, tumorABLE 2. Stepwise multiple regression analysis to assess independent determinants of acetylcholine saphenous vein
elaxation (model 1) and circulating Creactive protein levels (model 2)
ndependent variable B (SE) Beta t P 95% CI for B
odel 1
logCRP 14.10 5.93  0.27 2.38 .02 25.93–2.25
Constant 10.57 7.19 1.47 .14
odel 2
Atheroma 0.03 0.009 0.46 3.79 .0001 0.02–0.05
Constant 0.58 0.20 2.88 .006
odel 1: Dependent variable—% peak acetylcholine induced venous relaxation. Model 2: Dependent variable—circulating CRP level. Only variables with
atheroma, coronary atheroma extent score.
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PTable 2 and Figure 1). To examine whether the effects of
ender influenced venous endothelial function, the multi-
ariate analysis was repeated excluding data from the 6
emale patients recruited to the study. LogCRP (P  .02)
emained the only independent determinant of ACh-induced
enous relaxation. We also calculated EC50 for ACh-medi-
ted vasorelaxation (mean 340.2  51.2 nmol/L) according
o CRP concentrations (1 mg/L, 1 to 3 mg/L, and 3
g/L). Using 1-way analysis of variance, there was no
ssociation between the 3 groups (F  2.68, P  NS, data
ot shown). There was no correlation between contraction
f venous rings in response to phenylephrine and CRP
oncentration (r  .07, P  NS). There was no associa-
ion between saphenous vein endothelium-independent va-
odilatation, as demonstrated by venous relaxation in re-
ponse to SNP and baseline characteristics of patients.
To examine the influence of CRP on basal NO bioavail-
bility, we performed dose–response curves to phenyleph-
ine before and after exposure to L-NMMA. There was no
orrelation between logCRP levels and contraction in the
resence of L-NMMA (r  .05, P  NS).
eterminants of Circulating CRP
e then examined potential factors influencing circulating
RP levels in our cohort of patients with CAD. In univariate
nalysis there was a correlation between logCRP levels and
oronary atherosclerotic burden (r  .46, P  .0001), BMI
r .26, P .03), log glucose (r .31, P .01), and waist
ircumference (r .29, P .01). In a stepwise multivariate
egression model, coronary atherosclerotic burden (P 
0001) was the only independent predictor of plasma CRP
evels (Table 2 and Figure 1). Interestingly, there was no
orrelation between LDL cholesterol and HDL cholesterol
nd CRP levels.
iscussion
e have demonstrated a number of novel and potentially
mportant findings. Our results indicate that in patients
reated with statins, circulating CRP was the only indepen-
ent predictor of endothelial function in saphenous vein
ings ex vivo. In turn, the only independent predictor of
irculating CRP level was coronary atherosclerotic burden,
ith HDL cholesterol, LDL cholesterol, and other conven-
ional risk factors for cardiovascular disease having no
ndependent association with circulating CRP levels. Fur-
hermore, despite regular treatment with statins at doses that
ignificantly reduced LDL cholesterol, a sizeable proportion
f patients with CAD undergoing CABG surgery had CRP
evels within the “high-risk” range.
Medium- to long-term patency of saphenous vein grafts
s a major limitation to the use of venous conduits in
atients undergoing CABG surgery.13 It is estimated that byyears around 30% and by 10 years 40% to 60% of C
The Journal of Thoracicaphenous vein conduits occlude.13 The mechanisms lead-
ng to medium- and long-term graft failure remain unclear.
orphologic analysis of venous conduits has shown that
therosclerotic changes can occur as early as 6 months
ost-CABG surgery, with the incidence of these lesions
ncreasing to 30% 3 years postsurgery.13 Therefore, exam-
nation of the role of factors, such as endothelial dysfunction
nd systemic inflammation, which are known to be integral
o atheroma formation, in the context of venous grafts is
mportant.
eterminants of Saphenous Vein Endothelial Function
ndothelial dysfunction is an early detectable functional
hange in the development of atherosclerosis in native cor-
nary arteries.1,2 It has also been shown to be a powerful
redictor of future cardiovascular morbidity and mortality
n patients with CAD.1,2 This effect is in part due to loss of
O bioavailability with consequent reduction in endothelial
ntiatherogenic and antiplatelet effects.3,4 However, infor-
ation on endothelial function in venous conduits, such as
aphenous vein grafts of patients undergoing CABG sur-
ery, and its clinical implications remain limited. Saphe-
ous vein graft endothelial dysfunction predisposes to the
evelopment of neointimal proliferation,14 a process that
an be inhibited by increasing NO bioavailability.15 Recent
tudies also support a close correlation between endothelial
unction in saphenous vein and internal mammary and ra-
ial arteries.16 Therefore, the presence of saphenous vein
ndothelial dysfunction in patients with CAD undergoing
ABG surgery may be relevant to the progression of ath-
rosclerosis and its clinical complications in both venous
nd arterial conduits post-CABG surgery, as well as native
oronary arteries. Previous studies have demonstrated that
uring surgical vein harvest, there is a risk of significant
ndothelial denudation.13 This may introduce important in-
uences of the subendothelial layers on function of the
enous graft. For example, the extent of venous graft endo-
helial disruption is related to the risk of early thrombosis.17
n the present study, we took great care to avoid endothelial
oss, although the extent of endothelial loss was not for-
ally quantified using immunohistochemistry. As dis-
ussed, in routine clinical practice, preparation of venous
onduits prior to grafting often results in significant endo-
helial denudation, which may limit the clinical applicability
f our results. Nevertheless, in saphenous veins with good
ndothelial integrity (which one could argue should be a
oal during vein harvest), the extent of endothelial dysfunc-
ion is potentially important. Preoperative use of statins
ould address this issue. Furthermore, the effect of local and
ystemic CRP on endothelial loss warrants attention.
A number of factors are known to influence endothelial
unction in patients with CAD. Conventional risk factors for
AD (such as smoking, hypertension, abnormal lipid pro-
and Cardiovascular Surgery ● Volume 134, Number 2 339
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CSPle, and high glucose levels) lead to endothelial dysfunc-
ion,18 and in contrast, pharmacologic agents, such as an-
iotensin-converting enzyme (ACE) inhibitors and statins,
hich are commonly used in patients with CAD, improve
ndothelial function.19,20 In our group of patients who had a
ange of cardiovascular risk factors and were also treated
ith statins and ACE inhibitors, CRP emerged as the only
ndependent predictor of saphenous vein endothelial dys-
unction. This is highly suggestive that CRP directly influ-
nces the endothelium. Our study was not designed to
xamine the mechanisms by which CRP influences endo-
helial dysfunction. However, a number of in vitro studies
ndicate that CRP may influence endothelial function by
educing the bioavailability of NO.5,6 Verma and col-
eagues6 have shown that physiologic concentrations of
RP reduce the expression of endothelial nitric oxide syn-
hase in human arterial endothelial cells in culture. Other
tudies support a role for oxidative stress and CRP-mediated
ndothelial dysfunction.21
Recent studies have shown that patients with acute cor-
nary syndrome who respond to statin therapy by reducing
RP levels have a better clinical outcome than correspond-
ng individuals with higher levels of CRP.22,23 Similarly, in
atients with CAD, the progression of atherosclerosis is
ignificantly blunted in patients achieving lower levels of
RP with statins.24 Future clinical follow-up data on our
ohort of well-characterized patients would be of interest,
nd further work is required to identify the clinical impli-
ations and associations between CRP levels, statin therapy,
nd endothelial dysfunction on disease progression and
atency of saphenous vein conduits in patients undergoing
ABG surgery.
RP Levels and Statin Therapy
RP levels predict the incidence of future cardiovascular
vents.25 In patients with LDL cholesterol of 3.3 mmol/L
130 mg/dL), CRP levels of 1, 1 to 3, and  3 mg/L
ave been shown to correspond to low, medium, and high
isk of future cardiovascular events.26 Treatment with st-
tins reduces CRP levels independent of its effects on lipid
eduction.7,8 This process is thought to account for some of
he beneficial effects of statins in patients at risk of cardio-
ascular events, with the greatest benefit seen in patients
ith the largest fall in CRP.22-24 Interestingly, in our group
f patients undergoing CABG surgery, despite aggressive
eduction in LDL cholesterol in all patients to levels 1.6
mol/L (61.7 mg/dL) with regular use of simvastatin
reoperatively, CRP levels remained within the higher-risk
evel at 3 mg/L in over 25% of the patients.
RP Levels and Coronary Atheroma Burden
onsistent with postmortem studies,27 in the sample of
atients studied, we demonstrated that the extent of coro-
40 The Journal of Thoracic and Cardiovascular Surgery ● Auguary atherosclerotic burden was the only independent cor-
elate of circulating CRP levels. In view of our finding that
RP is a potentially important determinant of saphenous
ein endothelial function, this may be of clinical relevance.
t has recently been demonstrated that saphenous vein grafts
xpress CRP28 and that CRP can be released from the
oronary artery wall.29 Our data thus raise the intriguing
ossibility that the actual quantity of atheroma by contrib-
ting to local and systemic CRP levels may influence sa-
henous vein graft dysfunction and possibly graft failure, a
nding that warrants future studies.
onclusions
ur study demonstrated that circulating CRP level was the
nly independent predictor of endothelial dysfunction in
aphenous vein samples of patients with known coronary
rtery disease who were treated with statins. Furthermore, in
ur cohort of patients, “optimal” treatment with statins to
chieve LDL cholesterol levels of 1.6 mmol/L (61.7
g/dL) was insufficient to reduce systemic inflammation
as assessed by CRP) in a substantial proportion of patients.
he cross-sectional design of our study precluded investi-
ation of the role of CRP and endothelial dysfunction as
arkers of subsequent intimal growth in saphenous vein
rafts. Future longitudinal studies are required to investigate
hese changes and their potential clinical implications in
atients undergoing CABG surgery. Considering the likely
eleterious pathophysiologic role of inflammation in the
essel wall, combined with the relationship between CRP
nd venous endothelial dysfunction as demonstrated in the
urrent study, as well as CRP 3 mg/L despite optimal
tatin dosage for lipid control, further approaches to reduc-
ng inflammation are warranted. Targeting inflammation
nd CRP with more aggressive use of statins as used in the
ROVE-IT-TIMI 22 study22,23 or using more novel thera-
ies such as thiazolidinediones, which have significant anti-
nflammatory effects,30 are potentially available options that
ay improve both the longevity of venous conduits and
educe cardiovascular events in patients with severe CAD
lready “optimally” treated with statins.
Prof A.M. Shah is British Heart Foundation Professor of
ardiology, Dr M. Kearney was British Heart Foundation
ntermediate Fellow, and Dr N. Melikian is British Cardiac
ociety John Parker Research Fellow, at the Division of
ardiovascular Medicine, King’s College London School of
edicine at Guy’s, King’s College and St Thomas’ Hospi-
als, London, United Kingdom.
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